In 2015, global AIDS vaccine funding increased two percent from 2014, from US$840 million to US$862 million. This is still a far cry from the 2007 peak of US$961 million, but is also the greatest amount of investment seen in over five years.
While the US public sector remained the largest global contributor to AIDS vaccines R&D, the dual campaigns of the European AIDS Vaccine Initiative (EAVI2020) and the European HIV Vaccine Alliance (EHVA) boosted European public-sector investment to US$44 million in 2015.
Marginal increases from the philanthropic sector (three percent), led by the BMGF, and larger increases from industry (14 perfect) offset decreases from several public entities outside of the US and the European Commission.
In 2015, funding for AIDS vaccines were allocated predominantly to clinical trials (39 percent) followed by preclinical research (30 percent) and basic research (28 percent). These allocations represent only slight shifts from 2014 and reflect the continued emphasis on trials prompted by the start of several new trials in late 2014 and early 2015.